BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22160041)

  • 1. Novel antibody-based therapies for acute lymphoblastic leukemia.
    Hoelzer D
    Hematology Am Soc Hematol Educ Program; 2011; 2011():243-9. PubMed ID: 22160041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoimmunotherapy in acute lymphoblastic leukemia.
    Hoelzer D; Gökbuget N
    Blood Rev; 2012 Jan; 26(1):25-32. PubMed ID: 21958552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
    Hoelzer D
    Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antibody-based therapy for acute lymphoblastic leukaemia.
    Gökbuget N; Hoelzer D
    Best Pract Res Clin Haematol; 2006; 19(4):701-13. PubMed ID: 16997178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
    Le Jeune C; Thomas X
    Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects.
    Gökbuget N; Hoelzer D
    Ann Hematol; 2004 Apr; 83(4):201-5. PubMed ID: 14648023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of antibody therapy in ALL.
    Ai J; Advani A
    Br J Haematol; 2015 Feb; 168(4):471-80. PubMed ID: 25382151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N; Litzow MR
    Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
    Wei G; Wang J; Huang H; Zhao Y
    J Hematol Oncol; 2017 Aug; 10(1):150. PubMed ID: 28821272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody therapy for acute lymphoblastic leukemia.
    Portell CA; Advani AS
    Curr Hematol Malig Rep; 2012 Jun; 7(2):153-9. PubMed ID: 22422550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
    Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
    Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
    Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging biological therapies to treat acute lymphoblastic leukemia.
    Huguet F; Tavitian S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.
    Wang S; Peng L; Xu W; Zhou Y; Zhu Z; Kong Y; Leung S; Wang J; Yan X; Mi JQ
    Front Med; 2022 Feb; 16(1):139-149. PubMed ID: 34463907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies in acute lymphoblastic leukemia.
    Jabbour E; O'Brien S; Ravandi F; Kantarjian H
    Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry.
    Pevna M; Doubek M; Coupek P; Stehlikova O; Klabusay M
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):411-8. PubMed ID: 25066039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.